Seattle, July 27, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global pain management drugs market is estimated to be valued at US$ 76,415.7 million in 2022 and is expected to exhibit a CAGR of 4.1% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Pain Management Drugs Market:
Major players operating in market are focusing on launch of new drugs for pain management. For instance, in September 2017, Dr. Reddy's Laboratories Limited, a pharmaceutical company, launched anti-depressant, Bupropion Hydrochloride Extended Release Tablets, 150 mg and 300 mg, as well as muscle relaxant drug Metaxalone in the U.S. market. The anti-depressant drug is a generic equivalent version of Wellbutrin XL, Metaxalone, which is used for the treatment of skeletal muscle conditions such as pain and injury, is a generic equivalent version of the Skelaxin brand of King Pharmaceuticals Research and Development, Inc.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1697
Key Market Takeaways:
The global pain management drugs market is expected to exhibit a CAGR of 4.1% during the forecast period due to increasing adoption of inorganic strategies such as acquisition by key players in market. For instance, on July 1 2022, GlaxoSmithKline GSK plc, a pharmaceutical company, acquired Sierra Oncology, Inc., a late-stage clinical drug development biopharmaceutical company for development of targeted therapies for the treatment of rare forms of cancer and anemic diseases. The acquisition of Sierra Oncology includes momelotinib, a late-stage potential new medicine with a unique dual mechanism of action that may address the critical unmet medical needs of myelofibrosis patients with anemia. In addition, momelotinib complements GSK’s Blenrep (belantamab mafodotin). The acquisition builds on the company’s expertise in haematology and aligns with GSK’s strategy of building a strong portfolio of specialty medicines and vaccines.
North America region is expected to hold a dominant position in market over the forecast period, owing to research and development of new pain management solutions in the region. For instance, in April 2022, Eli Lilly and Company, a U.S. based pharmaceutical company, carried out research and development on new drug molecule for migraine, LY3451838, which is a ligand-directed, fully human antibody for the PACAP38 neuropeptide. It is being studied for the prevention of migraine and has passed out phase II clinical trials and currently in phase 3 clinical trials in 2022.
Competitive Landscape:
Key players operating in the global pain management drugs market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1697
Market Segmentation:
- Global Pain Management Drugs Market, By Drug Class:
- Opioids
- NSAIDs
- Anticonvulsants
- Antidepressants
- Others
- Global Pain Management Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Pain Management Drugs Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Region/Country
- North America
Related Market Intelligence Reports:
Small Molecule Injectable Drugs Market, by Drug Class (Chemotherapy, Small Molecule Antibiotics, Skeletal Muscle Relaxants, Analgesics, Anticoagulants, Anticonvulsants, Antivirals, and Others), by Indication (Oncology, Pain Management, Cardiovascular Diseases, Infectious Diseases, CNS Diseases, and Others), by Mode of Delivery (IV Set, Infusion Pump, Intravenous Injection, Intramuscular Injection, and Subcutaneous Injection), by End User (Hospitals, Ambulatory Clinics, Outpatient Facility, Infusion Therapy Center, Home Care, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
Spinal Cord Injury Therapeutics Market, by Injury Type (Complete Spinal Cord Injury and Incomplete Spinal Cord Injury), by Drug Type (Corticosteroids, Muscle Relaxants and Anti-spastic drugs, Non-steroidal Anti-inflammatory drugs (NSAIDs), Anti-depressants, Anticonvulsants, and Others), by Application (Autonomic Dysreflexia (AD), Spasticity & Inflammation, Pain Management, and Depression), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
